Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
Previous Symbol
CUSIP00972810
Phone847-279-6100
Debt
Debt-to-Equity Ratio1.13
Current Ratio3.94
Quick Ratio2.87
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio26.48
P/E Growth1.33
Sales & Book Value
Annual Sales$841.04 million
Price / Sales0.99
Cash Flow$0.4955 per share
Price / Cash13.36
Book Value$6.65 per share
Price / Book1.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,550,000.00
Net Margins-24.21%
Return on Equity-12.84%
Return on Assets-5.48%
Miscellaneous
Employees2,308
Outstanding Shares125,450,000
Market Cap$881.92 million
OptionableN/A
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) posted its quarterly earnings results on Wednesday, August, 1st. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by $0.14. The company earned $190.94 million during the quarter, compared to analyst estimates of $187.40 million. Akorn had a negative net margin of 24.21% and a negative return on equity of 12.84%. View Akorn's Earnings History.
What price target have analysts set for AKRX?
6 analysts have issued 1-year target prices for Akorn's shares. Their predictions range from $6.00 to $34.00. On average, they anticipate Akorn's stock price to reach $14.60 in the next twelve months. This suggests a possible upside of 121.2% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Array Biopharma (ARRY), Horizon Pharma (HZNP), Ultragenyx Pharmaceutical (RARE), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Madrigal Pharmaceuticals (MDGL), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), TESARO (TSRO), Mallinckrodt (MNK) and Heron Therapeutics (HRTX).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Rajat Rai, Chief Exec. Officer (Age 51)
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)
- Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by many different of institutional and retail investors. Top institutional investors include Seven Eight Capital LP (0.02%) and NJ State Employees Deferred Compensation Plan (0.02%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky and John N Kapoor. View Institutional Ownership Trends for Akorn.
Which major investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including Seven Eight Capital LP. Company insiders that have sold Akorn company stock in the last year include Brian Tambi and John N Kapoor. View Insider Buying and Selling for Akorn.
Which major investors are buying Akorn stock?
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $6.60.
How big of a company is Akorn?
Akorn has a market capitalization of $881.92 million and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
